An observational study in Pulmonary Embolism, sponsored by University Hospital, Strasbourg, France. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.
Sponsored by University Hospital, Strasbourg, France · Observational
Pulmonary embolism is a frequent and recurrent pathology, especially in the elderly. It is often preventable, with high mortality and morbidity, making it a major public health issue. The clinical presentation of pulmonary embolism is non-specific and very highly variable, ranging from asymptomatic thrombus diagnosed incidentally to sudden death. The current diagnosis of pulmonary embolism is based on several diagnostic techniques, mainly non-invasive, which should be used sequentially.
We propose to sample the volatile organic compounds using a device that allows them to be trapped on polymer cartridges. Sampling will be performed under monitoring of respiratory pressure and a capnograph to collect alveolar and upper respiratory tract air separately without contamination of the oral cavity or sinuses.
This exploratory metabolic analysis will be non-targeted (analysis of all molecules detectable without a priori).
The main objective of the study is to identify specific metabolic profiles to predict the results of ventilation-perfusion pulmonary tomoscintigraphy in subjects undergoing this examination for suspected acute pulmonary embolism.
Secondary purposes :
739 studies on the registry are indexed under Pulmonary Embolism; 159 are open to participants now.
This study's enrollment of 1 is below the median of 392 across 324 observational studies indexed under Pulmonary Embolism.
Browse Pulmonary Embolism studies →University Hospital, Strasbourg, France is the lead sponsor of 968 studies on the registry; 344 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients presenting to the Nuclear Medicine Department of our hospital for a pulmonary ventilation-perfusion tomoscintigraphy will be proposed to participate in the study
Exclusion Criteria:
≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy
Other: Pulmonary embolism diagnosis by nuclear medicine imaging
Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy
Other: Pulmonary embolism diagnosis by nuclear medicine imaging
nuclear medicine imaging
quantitative comparison of metabolic profiles
The quantitative variables compared between the two "contributive" groups are the relative quantities of volatile organic compounds (metabolites) detected by chromatographic techniques coupled with mass spectrometry in exhaled air samples.
Time frame: Metabolites are collected immediately before pulmonary tomoscintigraphy
Wells score or revised Geneva score
The first secondary outcome consists of the primary outcome (quantitative metabolic variables) to which are added quantitative variables of clinical probability score for pulmonary embolism (Wells score or revised Geneva score).
Time frame: Clinical scores are collected immediately before pulmonary tomoscintigraphy
number and location of deficient segments on ventilation-perfusion pulmonary tomoscintigraphy.
number and location of deficient segments on ventilation-perfusion pulmonary tomoscintigraphy.
Time frame: day 1
This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France